{"pmid":32358202,"pmcid":"PMC7199907","title":"SARS-CoV-2 productively infects human gut enterocytes.","text":["SARS-CoV-2 productively infects human gut enterocytes.","The virus severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) can cause coronavirus disease 2019 (COVID-19), an influenza-like disease that is primarily thought to infect the lungs with transmission via the respiratory route. However, clinical evidence suggests that the intestine may present another viral target organ. Indeed, the SARS-CoV-2 receptor angiotensin converting enzyme 2 (ACE2) is highly expressed on differentiated enterocytes. In human small intestinal organoids (hSIOs), enterocytes were readily infected by SARS-CoV and SARS-CoV-2 as demonstrated by confocal- and electron-microscopy. Consequently, significant titers of infectious viral particles were detected. mRNA expression analysis revealed strong induction of a generic viral response program. Hence, intestinal epithelium supports SARS-CoV-2 replication, and hSIOs serve as an experimental model for coronavirus infection and biology.","Science","Lamers, Mart M","Beumer, Joep","van der Vaart, Jelte","Knoops, Kevin","Puschhof, Jens","Breugem, Tim I","Ravelli, Raimond B G","Paul van Schayck, J","Mykytyn, Anna Z","Duimel, Hans Q","van Donselaar, Elly","Riesebosch, Samra","Kuijpers, Helma J H","Schippers, Debby","van de Wetering, Willine J","de Graaf, Miranda","Koopmans, Marion","Cuppen, Edwin","Peters, Peter J","Haagmans, Bart L","Clevers, Hans","32358202"],"abstract":["The virus severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) can cause coronavirus disease 2019 (COVID-19), an influenza-like disease that is primarily thought to infect the lungs with transmission via the respiratory route. However, clinical evidence suggests that the intestine may present another viral target organ. Indeed, the SARS-CoV-2 receptor angiotensin converting enzyme 2 (ACE2) is highly expressed on differentiated enterocytes. In human small intestinal organoids (hSIOs), enterocytes were readily infected by SARS-CoV and SARS-CoV-2 as demonstrated by confocal- and electron-microscopy. Consequently, significant titers of infectious viral particles were detected. mRNA expression analysis revealed strong induction of a generic viral response program. Hence, intestinal epithelium supports SARS-CoV-2 replication, and hSIOs serve as an experimental model for coronavirus infection and biology."],"journal":"Science","authors":["Lamers, Mart M","Beumer, Joep","van der Vaart, Jelte","Knoops, Kevin","Puschhof, Jens","Breugem, Tim I","Ravelli, Raimond B G","Paul van Schayck, J","Mykytyn, Anna Z","Duimel, Hans Q","van Donselaar, Elly","Riesebosch, Samra","Kuijpers, Helma J H","Schippers, Debby","van de Wetering, Willine J","de Graaf, Miranda","Koopmans, Marion","Cuppen, Edwin","Peters, Peter J","Haagmans, Bart L","Clevers, Hans"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358202","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1126/science.abc1669","topics":["Mechanism"],"weight":1,"_version_":1666138495294373888,"score":9.490897,"similar":[{"pmid":32405028,"title":"Infection of bat and human intestinal organoids by SARS-CoV-2.","text":["Infection of bat and human intestinal organoids by SARS-CoV-2.","A novel coronavirus-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-emerged in humans in Wuhan, China, in December 2019 and has since disseminated globally(1,2). As of April 16, 2020, the confirmed case count of coronavirus disease 2019 (COVID-19) had surpassed 2 million. Based on full-genome sequence analysis, SARS-CoV-2 shows high homology to SARS-related coronaviruses identified in horseshoe bats(1,2). Here we show the establishment and characterization of expandable intestinal organoids derived from horseshoe bats of the Rhinolophus sinicus species that can recapitulate bat intestinal epithelium. These bat enteroids are fully susceptible to SARS-CoV-2 infection and sustain robust viral replication. Development of gastrointestinal symptoms in some patients with COVID-19 and detection of viral RNA in fecal specimens suggest that SARS-CoV-2 might cause enteric, in addition to respiratory, infection(3,4). Here we demonstrate active replication of SARS-CoV-2 in human intestinal organoids and isolation of infectious virus from the stool specimen of a patient with diarrheal COVID-19. Collectively, we established the first expandable organoid culture system of bat intestinal epithelium and present evidence that SARS-CoV-2 can infect bat intestinal cells. The robust SARS-CoV-2 replication in human intestinal organoids suggests that the human intestinal tract might be a transmission route of SARS-CoV-2.","Nat Med","Zhou, Jie","Li, Cun","Liu, Xiaojuan","Chiu, Man Chun","Zhao, Xiaoyu","Wang, Dong","Wei, Yuxuan","Lee, Andrew","Zhang, Anna Jinxia","Chu, Hin","Cai, Jian-Piao","Yip, Cyril Chik-Yan","Chan, Ivy Hau-Yee","Wong, Kenneth Kak-Yuen","Tsang, Owen Tak-Yin","Chan, Kwok-Hung","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chen, Honglin","Yuen, Kwok Yung","32405028"],"abstract":["A novel coronavirus-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-emerged in humans in Wuhan, China, in December 2019 and has since disseminated globally(1,2). As of April 16, 2020, the confirmed case count of coronavirus disease 2019 (COVID-19) had surpassed 2 million. Based on full-genome sequence analysis, SARS-CoV-2 shows high homology to SARS-related coronaviruses identified in horseshoe bats(1,2). Here we show the establishment and characterization of expandable intestinal organoids derived from horseshoe bats of the Rhinolophus sinicus species that can recapitulate bat intestinal epithelium. These bat enteroids are fully susceptible to SARS-CoV-2 infection and sustain robust viral replication. Development of gastrointestinal symptoms in some patients with COVID-19 and detection of viral RNA in fecal specimens suggest that SARS-CoV-2 might cause enteric, in addition to respiratory, infection(3,4). Here we demonstrate active replication of SARS-CoV-2 in human intestinal organoids and isolation of infectious virus from the stool specimen of a patient with diarrheal COVID-19. Collectively, we established the first expandable organoid culture system of bat intestinal epithelium and present evidence that SARS-CoV-2 can infect bat intestinal cells. The robust SARS-CoV-2 replication in human intestinal organoids suggests that the human intestinal tract might be a transmission route of SARS-CoV-2."],"journal":"Nat Med","authors":["Zhou, Jie","Li, Cun","Liu, Xiaojuan","Chiu, Man Chun","Zhao, Xiaoyu","Wang, Dong","Wei, Yuxuan","Lee, Andrew","Zhang, Anna Jinxia","Chu, Hin","Cai, Jian-Piao","Yip, Cyril Chik-Yan","Chan, Ivy Hau-Yee","Wong, Kenneth Kak-Yuen","Tsang, Owen Tak-Yin","Chan, Kwok-Hung","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chen, Honglin","Yuen, Kwok Yung"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405028","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41591-020-0912-6","locations":["Wuhan","China","horseshoe","Rhinolophus"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Transmission"],"weight":1,"_version_":1666950579830652928,"score":373.4017},{"pmid":32404436,"title":"TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes.","text":["TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes.","Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA are frequently observed in COVID-19 patients. However, it is unclear whether SARS-CoV-2 replicates in the human intestine and contributes to possible fecal-oral transmission. Here, we report productive infection of SARS-CoV-2 in ACE2(+) mature enterocytes in human small intestinal enteroids. Expression of two mucosa-specific serine proteases, TMPRSS2 and TMPRSS4, facilitated SARS-CoV-2 spike fusogenic activity and promoted virus entry into host cells. We also demonstrate that viruses released into the intestinal lumen were inactivated by simulated human colonic fluid, and infectious virus was not recovered from the stool specimens of COVID-19 patients. Our results highlight the intestine as a potential site of SARS-CoV-2 replication, which may contribute to local and systemic illness and overall disease progression.","Sci Immunol","Zang, Ruochen","Gomez Castro, Maria Florencia","McCune, Broc T","Zeng, Qiru","Rothlauf, Paul W","Sonnek, Naomi M","Liu, Zhuoming","Brulois, Kevin F","Wang, Xin","Greenberg, Harry B","Diamond, Michael S","Ciorba, Matthew A","Whelan, Sean P J","Ding, Siyuan","32404436"],"abstract":["Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA are frequently observed in COVID-19 patients. However, it is unclear whether SARS-CoV-2 replicates in the human intestine and contributes to possible fecal-oral transmission. Here, we report productive infection of SARS-CoV-2 in ACE2(+) mature enterocytes in human small intestinal enteroids. Expression of two mucosa-specific serine proteases, TMPRSS2 and TMPRSS4, facilitated SARS-CoV-2 spike fusogenic activity and promoted virus entry into host cells. We also demonstrate that viruses released into the intestinal lumen were inactivated by simulated human colonic fluid, and infectious virus was not recovered from the stool specimens of COVID-19 patients. Our results highlight the intestine as a potential site of SARS-CoV-2 replication, which may contribute to local and systemic illness and overall disease progression."],"journal":"Sci Immunol","authors":["Zang, Ruochen","Gomez Castro, Maria Florencia","McCune, Broc T","Zeng, Qiru","Rothlauf, Paul W","Sonnek, Naomi M","Liu, Zhuoming","Brulois, Kevin F","Wang, Xin","Greenberg, Harry B","Diamond, Michael S","Ciorba, Matthew A","Whelan, Sean P J","Ding, Siyuan"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32404436","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1126/sciimmunol.abc3582","e_drugs":["Serine"],"topics":["Mechanism"],"weight":1,"_version_":1666950579750961154,"score":369.65555},{"pmid":32311451,"pmcid":"PMC7165079","title":"Specific ACE2 Expression in Small Intestinal Enterocytes may Cause Gastrointestinal Symptoms and Injury after 2019-nCoV Infection.","text":["Specific ACE2 Expression in Small Intestinal Enterocytes may Cause Gastrointestinal Symptoms and Injury after 2019-nCoV Infection.","The coronavirus disease 2019 (COVID-19) was first reported in Wuhan, China and rapidly spread in other countries in December 2019. The infected patients presented with fever, respiratory symptoms, sometimes with digestive and other systemic manifestations, and some progressed with a severe acute respiratory syndrome or even death. Associated digestive symptoms were frequently observed in the patients, with an unknown significance and mechanism. ACE2, as the major known functional receptor of the 2019 novel coronavirus (2019-nCoV) attracted our attention. We collected the clinical data of the 2019-nCoV-infected patients from published studies and extracted the data about the incidence of gastrointestinal symptoms. Furthermore, we used online datasets to analyze ACE2 expression in different human organs, especially in the small intestine, to explore the relationship between ACE2 expression patterns and clinical symptoms. We found that diarrhea accounted for a notable proportion of COVID-19 patients, ranging from 8.0% to 12.9%. The results reveal that ACE2 mRNA and protein are highly expressed in the small intestinal enterocytes but not in the goblet cells or intestinal immune cells. High expression of ACE2 on the surface cells in the digestive tract may lead to gastrointestinal symptoms and inflammation susceptibility. Overall, digestive symptoms were common in the COVID-19 patients. ACE2 expression on surface cells of the small intestine may mediate the invasion and amplification of the virus and activation of gastrointestinal inflammation. It is a possible mechanism of digestive symptoms in the COVID-19 patients and explains the presence of the virus in patients' stool samples. The study also highlights the necessity of taking stool samples for suspected patients to help in early diagnosis and assessment of disease status.","Int J Infect Dis","Zhang, Hui","Li, Hong-Bao","Lyu, Jian-Rui","Lei, Xiao-Ming","Li, Wei","Wu, Gang","Lyu, Jun","Dai, Zhi-Ming","32311451"],"abstract":["The coronavirus disease 2019 (COVID-19) was first reported in Wuhan, China and rapidly spread in other countries in December 2019. The infected patients presented with fever, respiratory symptoms, sometimes with digestive and other systemic manifestations, and some progressed with a severe acute respiratory syndrome or even death. Associated digestive symptoms were frequently observed in the patients, with an unknown significance and mechanism. ACE2, as the major known functional receptor of the 2019 novel coronavirus (2019-nCoV) attracted our attention. We collected the clinical data of the 2019-nCoV-infected patients from published studies and extracted the data about the incidence of gastrointestinal symptoms. Furthermore, we used online datasets to analyze ACE2 expression in different human organs, especially in the small intestine, to explore the relationship between ACE2 expression patterns and clinical symptoms. We found that diarrhea accounted for a notable proportion of COVID-19 patients, ranging from 8.0% to 12.9%. The results reveal that ACE2 mRNA and protein are highly expressed in the small intestinal enterocytes but not in the goblet cells or intestinal immune cells. High expression of ACE2 on the surface cells in the digestive tract may lead to gastrointestinal symptoms and inflammation susceptibility. Overall, digestive symptoms were common in the COVID-19 patients. ACE2 expression on surface cells of the small intestine may mediate the invasion and amplification of the virus and activation of gastrointestinal inflammation. It is a possible mechanism of digestive symptoms in the COVID-19 patients and explains the presence of the virus in patients' stool samples. The study also highlights the necessity of taking stool samples for suspected patients to help in early diagnosis and assessment of disease status."],"journal":"Int J Infect Dis","authors":["Zhang, Hui","Li, Hong-Bao","Lyu, Jian-Rui","Lei, Xiao-Ming","Li, Wei","Wu, Gang","Lyu, Jun","Dai, Zhi-Ming"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311451","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ijid.2020.04.027","keywords":["2019-ncov","ace2","covid-19","diarrhea","small intestine"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491173470209,"score":347.53238},{"pmid":32430279,"title":"Gut microbiota and Covid-19- possible link and implications.","text":["Gut microbiota and Covid-19- possible link and implications.","Covid-19 is a major pandemic facing the world today caused by SARS-CoV-2 which has implications on our understanding of infectious diseases. Although, SARS-Cov-2 primarily causes lung infection through binding of ACE2 receptors present on the alveolar epithelial cells, yet it was recently reported that SARS-CoV-2 RNA was found in the faeces of infected patients. Interestingly, the intestinal epithelial cells particularly the enterocytes of the small intestine also express ACE2 receptors. Role of the gut microbiota in influencing lung diseases has been well articulated. It is also known that respiratory virus infection causes perturbations in the gut microbiota. Diet, environmental factors and genetics play an important role in shaping gut microbiota which can influence immunity. Gut microbiota diversity is decreased in old age and Covid-19 has been mainly fatal in elderly patients which again points to the role the gut microbiota may play in this disease. Improving gut microbiota profile by personalized nutrition and supplementation known to improve immunity can be one of the prophylactic ways by which the impact of this disease can be minimized in old people and immune-compromised patients. More trials may be initiated to see the effect of co-supplementation of personalized functional food including prebiotics/probiotics along with current therapies.","Virus Res","Dhar, Debojyoti","Mohanty, Abhishek","32430279"],"abstract":["Covid-19 is a major pandemic facing the world today caused by SARS-CoV-2 which has implications on our understanding of infectious diseases. Although, SARS-Cov-2 primarily causes lung infection through binding of ACE2 receptors present on the alveolar epithelial cells, yet it was recently reported that SARS-CoV-2 RNA was found in the faeces of infected patients. Interestingly, the intestinal epithelial cells particularly the enterocytes of the small intestine also express ACE2 receptors. Role of the gut microbiota in influencing lung diseases has been well articulated. It is also known that respiratory virus infection causes perturbations in the gut microbiota. Diet, environmental factors and genetics play an important role in shaping gut microbiota which can influence immunity. Gut microbiota diversity is decreased in old age and Covid-19 has been mainly fatal in elderly patients which again points to the role the gut microbiota may play in this disease. Improving gut microbiota profile by personalized nutrition and supplementation known to improve immunity can be one of the prophylactic ways by which the impact of this disease can be minimized in old people and immune-compromised patients. More trials may be initiated to see the effect of co-supplementation of personalized functional food including prebiotics/probiotics along with current therapies."],"journal":"Virus Res","authors":["Dhar, Debojyoti","Mohanty, Abhishek"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32430279","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.virusres.2020.198018","keywords":["covid-19","diet","dysbiosis","gut microbiome","immunity","lung microbiota","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288381018112,"score":308.5585},{"pmid":32333601,"pmcid":"PMC7188157","title":"Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD.","text":["Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD.","BACKGROUND: Patients with inflammatory bowel disease (IBD) have intestinal inflammation and are treated with immune-modulating medications. In the face of the coronavirus disease-19 pandemic, we do not know whether patients with IBD will be more susceptible to infection or disease. We hypothesized that the viral entry molecules angiotensin I converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) are expressed in the intestine. We further hypothesized that their expression could be affected by inflammation or medication usage. METHODS: We examined the expression of Ace2 and Tmprss2 by quantitative polymerase chain reacion in animal models of IBD. Publicly available data from organoids and mucosal biopsies from patients with IBD were examined for expression of ACE2 and TMPRSS2. We conducted RNA sequencing for CD11b-enriched cells and peripheral and lamina propria T-cells from well-annotated patient samples. RESULTS: The molecules ACE2 and TMPRSS2 were abundantly expressed in the ileum and colon and had high expression in intestinal epithelial cells. In animal models, inflammation led to downregulation of epithelial Ace2. Expression of ACE2 and TMPRSS2 was not increased in samples from patients with compared with those of control patients. In CD11b-enriched cells but not T-cells, the level of expression of ACE2 and TMPRSS2 in the mucosa was comparable to other functional mucosal genes and was not affected by inflammation. Anti-tumor necrosis factor drugs, vedolizumab, ustekinumab, and steroids were linked to significantly lower expression of ACE2 in CD11b-enriched cells. CONCLUSIONS: The viral entry molecules ACE2 and TMPRSS2 are expressed in the ileum and colon. Patients with IBD do not have higher expression during inflammation; medical therapy is associated with lower levels of ACE2. These data provide reassurance for patients with IBD.","Inflamm Bowel Dis","Burgueno, Juan F","Reich, Adrian","Hazime, Hajar","Quintero, Maria A","Irina, Fernandez","Fritsch, Julia","Santander, Ana M","Brito, Nivis","Damas, Oriana M","Deshpande, Amar","Kerman, David H","Zhang, Lanyu","Gao, Zhen","Ban, Yuguang","Wang, Lily","Pignac-Kobinger, Judith","Abreu, Maria T","32333601"],"abstract":["BACKGROUND: Patients with inflammatory bowel disease (IBD) have intestinal inflammation and are treated with immune-modulating medications. In the face of the coronavirus disease-19 pandemic, we do not know whether patients with IBD will be more susceptible to infection or disease. We hypothesized that the viral entry molecules angiotensin I converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) are expressed in the intestine. We further hypothesized that their expression could be affected by inflammation or medication usage. METHODS: We examined the expression of Ace2 and Tmprss2 by quantitative polymerase chain reacion in animal models of IBD. Publicly available data from organoids and mucosal biopsies from patients with IBD were examined for expression of ACE2 and TMPRSS2. We conducted RNA sequencing for CD11b-enriched cells and peripheral and lamina propria T-cells from well-annotated patient samples. RESULTS: The molecules ACE2 and TMPRSS2 were abundantly expressed in the ileum and colon and had high expression in intestinal epithelial cells. In animal models, inflammation led to downregulation of epithelial Ace2. Expression of ACE2 and TMPRSS2 was not increased in samples from patients with compared with those of control patients. In CD11b-enriched cells but not T-cells, the level of expression of ACE2 and TMPRSS2 in the mucosa was comparable to other functional mucosal genes and was not affected by inflammation. Anti-tumor necrosis factor drugs, vedolizumab, ustekinumab, and steroids were linked to significantly lower expression of ACE2 in CD11b-enriched cells. CONCLUSIONS: The viral entry molecules ACE2 and TMPRSS2 are expressed in the ileum and colon. Patients with IBD do not have higher expression during inflammation; medical therapy is associated with lower levels of ACE2. These data provide reassurance for patients with IBD."],"journal":"Inflamm Bowel Dis","authors":["Burgueno, Juan F","Reich, Adrian","Hazime, Hajar","Quintero, Maria A","Irina, Fernandez","Fritsch, Julia","Santander, Ana M","Brito, Nivis","Damas, Oriana M","Deshpande, Amar","Kerman, David H","Zhang, Lanyu","Gao, Zhen","Ban, Yuguang","Wang, Lily","Pignac-Kobinger, Judith","Abreu, Maria T"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333601","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1093/ibd/izaa085","keywords":["crohn disease","coronavirus","ulcerative colitis"],"locations":["vedolizumab"],"e_drugs":["Serine","Ustekinumab","Steroids","vedolizumab"],"topics":["Mechanism"],"weight":1,"_version_":1666138494047617024,"score":272.09213}]}